TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29273043

Group type: EXPERIMENTAL
Intervention: FACT-M questionnaire
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: FACT-M scores
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MIDs for FACT-M domains
Number of subjects: 70
Study: 29273054

Group type: EXPERIMENTAL
Intervention: NG12-1 vasoconstrictor, applied topically, 30 daily treatments before radiotherapy.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control area (no treatment).
Number of subjects: 9
Study: 29273071

Group type: EXPERIMENTAL
Intervention: miR-22
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: miR-486-3p
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: miR-382
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study: 29273095

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 440

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 440
Study: 29273113

Group type: EXPERIMENTAL
Intervention: Social empowerment program (Creating Opportunities through Mentoring, Parental Involvement and Safe Spaces) with 40 fixed-curriculum, mentor-facilitated sessions once a week for 10 months and 10 caregiver discussion sessions once a month for the same period
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control group (no exposure to the curriculum)
Number of subjects: 919
Study: 29273410

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200mg intravenously every 3 weeks until loss of clinical benefit
Number of subjects: 315
Study: 29273636

Group type: EXPERIMENTAL
Intervention: Young patients with ACS (aged ≤45 years)
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Older patients with ACS (aged >45 years)
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Men aged ≤45 years with ACS
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Women aged ≤45 years with ACS
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Younger women with ACS compared to younger men
Number of subjects: 1182
Study: 29273649

Group type: EXPERIMENTAL
Intervention: Cancer incidence rates among females
Number of subjects: 15840

Group type: EXPERIMENTAL
Intervention: Cancer incidence rates among males
Number of subjects: 15840

Group type: EXPERIMENTAL
Intervention: Common cancer diagnoses among females
Number of subjects: 15840

Group type: EXPERIMENTAL
Intervention: Common cancer diagnoses among males
Number of subjects: 15840

Group type: COMPARATOR
Intervention: Comparison of ASIR between genders
Number of subjects: 15840

Group type: EXPERIMENTAL
Intervention: Common cancer types in children and adolescents
Number of subjects: 15840

Group type: EXPERIMENTAL
Intervention: Leading cancer types in adults
Number of subjects: 15840
Study: 29273652

Group type: EXPERIMENTAL
Intervention: GARFIELD-AF risk tool
Number of subjects: 39898

Group type: COMPARATOR
Intervention: CHA
Number of subjects: 39898
Study: 29274015

Group type: EXPERIMENTAL
Intervention: Electronic monitoring device and behavioral feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29274193

Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg once daily for 6 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg once daily for 8 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Adverse events reported in 63.2% of patients (43/68), mainly grade 1/2, none led to treatment discontinuation.
Number of subjects: 68
Study: 29274733

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Treatment (CRT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 29275146

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, levofloxacin, or fosfomycin (antibiotic prophylaxis)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: TRUS-Bx procedure
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 294
Study: 29275778

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus nutrition psychoeducation (MINP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nutrition psychoeducation (NP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 31
Study: 29275821

Group type: EXPERIMENTAL
Intervention: Eunice Kennedy Shriver National Institute of Child Health and Human Development Study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INTERGROWTH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: World Health Organization Multicentre Growth Reference Study
Number of subjects: 0
Study: 29275855

Group type: EXPERIMENTAL
Intervention: Low epIQ subgroup (epIQ <90)
Number of subjects: 292
Study: 29275926

Group type: EXPERIMENTAL
Intervention: Maximal PEEP level during the first course of mechanical ventilation
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Variation in PEEP levels between neonatal centers
Number of subjects: 278
Study: 29275946

Group type: EXPERIMENTAL
Intervention: Predefined ECG abnormalities (including nonsinus rhythm, multiple premature ventricular conductions, short PR interval, first-degree atrioventricular block, complete left bundle branch block, Q wave/T wave/ST-segment abnormalities)
Number of subjects: 3416

Group type: EXPERIMENTAL
Intervention: Any ECG abnormality
Number of subjects: 3416

Group type: EXPERIMENTAL
Intervention: Combination of specific ECG abnormalities
Number of subjects: 3416
Study: 29276022

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 mg/kg or 1.8 mg/kg) plus bendamustine (70 mg/m2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg) plus bendamustine (80 mg/m2)
Number of subjects: 65
Study: 29276625

Group type: EXPERIMENTAL
Intervention: Epicardial transplantation of atrial appendage micrografts in a fibrin gel covered with a tissue-engineered ECM sheet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Epicardial transplantation of atrial appendage micrografts
Number of subjects: 6

Group type: COMPARATOR
Intervention: Routine CABG surgery (control group)
Number of subjects: 6
Study: 29276860

Group type: EXPERIMENTAL
Intervention: Low-protein overfeeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard, high-carbohydrate, high-fat, high-protein, low-protein diets
Number of subjects: 0
Study: 29277374

Group type: EXPERIMENTAL
Intervention: Aphasia therapy with aerobic exercise via bicycle ergometer (n = 5)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aphasia therapy with stretching (n = 2)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Aphasia therapy alone (Block 1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n = 4 participants)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Stretching (n = 1 participant)
Number of subjects: 7
Study: 29278006

Group type: EXPERIMENTAL
Intervention: Remission/Low Disease Activity (LDA) at Week 24
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low Disease Activity (LDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remission/LDA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 29279281

Group type: EXPERIMENTAL
Intervention: Single dose of 0.5 mL PCV13 in previously vaccinated subjects (n=284)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Double dose of 0.5 mL PCV13 in previously vaccinated subjects (n=288)
Number of subjects: 883
Study: 29279305

Group type: EXPERIMENTAL
Intervention: Composite Cerebellar Functional Severity (CCFS) Scale
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 383

Group type: COMPARATOR
Intervention: CCFS and SARA scales
Number of subjects: 383
Study: 29280309

Group type: EXPERIMENTAL
Intervention: 5% protein diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 15% protein diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 25% protein diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dietary fat and protein
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Change in fat mass and weight
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Baseline fat cell size (FCS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Interaction between glucose disposal and FCS
Number of subjects: 23
Study: 29280355

Group type: EXPERIMENTAL
Intervention: 50, 125, 300, or 600 mg of testosterone enanthate weekly injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2.5 mg dutasteride daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 0
Study: 29280716

Group type: EXPERIMENTAL
Intervention: Test of Sensory Functions in Infants
Number of subjects: 60
Study: 29280762

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.2 mg/kg with AVD (doxorubicin, vinblastine, dacarbazine)
Number of subjects: 6
Study: 29280921

Group type: EXPERIMENTAL
Intervention: Simplified definition of non-alcoholic steato-hepatitis (NASH) that does not require the presence of steatosis and the presence of both lobular inflammation and ballooning
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Standard definitions of NASH
Number of subjects: 1081
Study: 29281086

Group type: EXPERIMENTAL
Intervention: Antiplatelet (AP) monotherapy
Number of subjects: 51270

Group type: COMPARATOR
Intervention: Anticoagulant (AC) monotherapy
Number of subjects: 51270

Group type: EXPERIMENTAL
Intervention: AP monotherapy
Number of subjects: 51270

Group type: COMPARATOR
Intervention: AC monotherapy
Number of subjects: 51270

Group type: EXPERIMENTAL
Intervention: AP + AC and no antithrombotic therapy
Number of subjects: 51270
Study: 29281579

Group type: EXPERIMENTAL
Intervention: MRI examinations at 1.5 Tesla
Number of subjects: 1509
Study: 29282024

Group type: EXPERIMENTAL
Intervention: Emotion regulation individual therapy (ERITA) for 12 weeks
Number of subjects: 17
Study: 29282032

Group type: EXPERIMENTAL
Intervention: Riociguat adjusted from 1 mg three times daily (tid) to a maximum of 2.5 mg tid
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 300
Study: 29282054

Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational program (EDU; n=112)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (CON; n=127)
Number of subjects: 239
Study: 29282090

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5.0 mg BID for Cohort 1, 2.5 mg BID for Cohort 2, 3.0 mg BID for Cohort 3)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tofacitinib (oral solution, grape flavor)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tofacitinib (multiple-dose, twice daily for 5 days)
Number of subjects: 26
Study: 29282099

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules for six months
Number of subjects: 0
Study: 29282109

Group type: EXPERIMENTAL
Intervention: Standardized patient training intervention for healthcare workers (HCWs)
Number of subjects: 240
Study: 29282154

Group type: EXPERIMENTAL
Intervention: Pre-paid material incentive (iPad mini 2) with in-person recruitment and intervention plus virtual simulation
Number of subjects: 989

Group type: COMPARATOR
Intervention: Monetary reward ($100 gift card) conditional on completion with email recruitment and vignette-based questionnaire
Number of subjects: 989
Study: 29282263

Group type: EXPERIMENTAL
Intervention: 2-D ultrasound shear wave elastography (SWE) in fetuses of women with TPL requiring corticosteroids
Number of subjects: 2

Group type: COMPARATOR
Intervention: 2-D ultrasound shear wave elastography (SWE) in fetuses of women with uncomplicated pregnancies
Number of subjects: 2
Study: 29282271

Group type: EXPERIMENTAL
Intervention: Circulating tumour cells (CTCs) detection in peripheral blood samples during yearly screening rounds for 3 years plus a 1-year follow-up.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Low-dose chest CT (LDCT) during yearly screening rounds for 3 years plus a 1-year follow-up.
Number of subjects: 600
Study: 29282329

Group type: EXPERIMENTAL
Intervention: miRNA levels in CSF from prodromal HD participants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diagnosed HD participants
Number of subjects: 60
Study: 29282548

Group type: EXPERIMENTAL
Intervention: High-resolution peripheral quantitative computerized tomography (HRpQCT)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Hip QCT
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Calcaneus texture analysis
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Biochemical markers
Number of subjects: 1575
Study: 29282676

Group type: EXPERIMENTAL
Intervention: Ambrisentan (Volibris tablet 2.5 mg)
Number of subjects: 702
Study: 29282881

Group type: EXPERIMENTAL
Intervention: Children with overweight/obesity (≥ 85th BMI-for-age percentile)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Congruent trial mean accuracy and reaction time
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Incongruent trials
Number of subjects: 233
Study: 29284010

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg administered every 2 weeks for up to 2 years or until disease progression/unacceptable toxicity
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 23
Study: 29284181

Group type: EXPERIMENTAL
Intervention: T-Track assay
Number of subjects: 0
Study: 29284202

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 26
Study: 29284435

Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 0
Study: 29284455

Group type: EXPERIMENTAL
Intervention: Combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK) and accelerated corneal collagen cross-linking (CXL) after intracorneal ring segment (ICRS) implantation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ICRS implantation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined tPRK and CXL after ICRS implantation
Number of subjects: 23
Study: 29284461

Group type: EXPERIMENTAL
Intervention: 405 nm light-emitting diode device
Number of subjects: 28

Group type: COMPARATOR
Intervention: Commercial image-processing based plaque-imaging device
Number of subjects: 28
Study: 29284510

Group type: EXPERIMENTAL
Intervention: Low-dose, prophylactic naloxone infusion
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 29284521

Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise group (HBRX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control group (CON)
Number of subjects: 40
Study: 29284530

Group type: EXPERIMENTAL
Intervention: Fimasartan standard SBP control (SBP < 140 mmHg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fimasartan strict SBP control (SBP < 130 mmHg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan standard SBP control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan strict SBP control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fimasartan (after 24 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan (after 24 weeks)
Number of subjects: 0
Study: 29284596

Group type: EXPERIMENTAL
Intervention: High-throughput sequencing (HTS) of measurable residual disease (MRD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induction chemotherapy
Number of subjects: 0
Study: 29284607

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Weight Loss plus Exercise (WLEX)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No Treatment (Control)
Number of subjects: 95
Study: 29285038

Group type: EXPERIMENTAL
Intervention: Docetaxel and Gemcitabine (Neoadjuvant Chemotherapy)
Number of subjects: 98
Study: 29285668

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m² administered in second-(or later) setting, median of two cycles.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m²
Number of subjects: 65
Study: 29288065

Group type: EXPERIMENTAL
Intervention: Euclidean length measurement for urinary incontinence severity
Number of subjects: 0
Study: 29288159

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study: 29288176

Group type: EXPERIMENTAL
Intervention: bDMARD treatment
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index score
Number of subjects: 1352
Study: 29288237

Group type: EXPERIMENTAL
Intervention: Genomics-driven precision medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29288549

Group type: EXPERIMENTAL
Intervention: βAir device containing allogeneic human pancreatic islets
Number of subjects: 4
Study: 29288911

Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Perampanel secondary monotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Perampanel adjunctive treatment
Number of subjects: 60
Study: 29289501

Group type: EXPERIMENTAL
Intervention: Closed suction drains
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative pressure drains
Number of subjects: 0
Study: 29289757

Group type: EXPERIMENTAL
Intervention: Tandem autologous hematopoietic stem cell transplant (AHSCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salvage therapy
Number of subjects: 0
Study: 29289814

Group type: EXPERIMENTAL
Intervention: hrHPV testing of Evalyn self-collection device
Number of subjects: 310

Group type: COMPARATOR
Intervention: Physician-specimen
Number of subjects: 310
Study: 29289939

Group type: EXPERIMENTAL
Intervention: Low neighbourhood SES tertile
Number of subjects: 1645

Group type: COMPARATOR
Intervention: High neighbourhood SES tertile
Number of subjects: 1645
Study: 29290251

Group type: EXPERIMENTAL
Intervention: DLL3-high expression (positive in at least 50% of cancer cells)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: DLL3 expression status
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 63
Study: 29290515

Group type: EXPERIMENTAL
Intervention: Fixed airflow obstruction (FAO) defined as post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity ≤70%
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Fixed airflow obstruction (FAO)
Number of subjects: 186
Study: 29290601

Group type: EXPERIMENTAL
Intervention: VICI VENOUS STENT
Number of subjects: 30
Study: 29290809

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 25
Study: 29292064

Group type: EXPERIMENTAL
Intervention: DREAMS 2G (drug-eluting absorbable metal scaffold)
Number of subjects: 123
Study: 29292203

Group type: EXPERIMENTAL
Intervention: Prednisone-Trial
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oxantel-Trial
Number of subjects: 2
Study: 29292311

Group type: EXPERIMENTAL
Intervention: Project Zero Exposure intervention (motivational interviews, feedback on child biomarker and home air quality, website, video, self-help materials)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Project Zero Exposure intervention
Number of subjects: 26
Study: 29292843

Group type: EXPERIMENTAL
Intervention: Ontuxizumab at 12 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ontuxizumab
Number of subjects: 27
Study: 29293889

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg od
Number of subjects: 50
Study: 29293893

Group type: EXPERIMENTAL
Intervention: Fosmidomycin-piperaquine (30 mg/kg twice daily for fosmidomycin and 16 mg/kg once daily for piperaquine for 3 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fosmidomycin-piperaquine
Number of subjects: 100
Study: 29293895

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus Lamivudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29293942

Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 170

Group type: COMPARATOR
Intervention: Uninfected control participants
Number of subjects: 170
Study: 29294006

Group type: EXPERIMENTAL
Intervention: PDK4 expression in PBMCs and adipose tissue
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PDK4 expression in PBMCs
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FFAs
Number of subjects: 10
Study: 29296107

Group type: EXPERIMENTAL
Intervention: Omalizumab with rapid oral immunotherapy (OIT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Long-term maintenance dosing of food allergens
Number of subjects: 34
Study: 29296283

Group type: EXPERIMENTAL
Intervention: Patients who developed heart failure (HF) after STEMI
Number of subjects: 1459

Group type: COMPARATOR
Intervention: Patients without heart failure (controls)
Number of subjects: 1459

Group type: EXPERIMENTAL
Intervention: Crude incidence rate of HF after STEMI
Number of subjects: 1459

Group type: EXPERIMENTAL
Intervention: Peak creatine kinase MB (CK-MB) levels
Number of subjects: 1459

Group type: EXPERIMENTAL
Intervention: Left anterior descending artery (LAD) culprit lesion
Number of subjects: 1459
Study: 29296710

Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus (EBV) DNA in cell-free blood at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus (EBV) DNA in cell-free blood 8 days after initiation of therapy
Number of subjects: 0
Study: 29296707

Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PT-Cy) at 0 mg/kg in cohort 1
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PT-Cy) at 50 mg/kg in cohort 2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PT-Cy) at 100 mg/kg in cohort 3
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GVHD)
Number of subjects: 23
Study: 29296751

Group type: EXPERIMENTAL
Intervention: PF-06747143
Number of subjects: 0
Study: 29296758

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) 1.2 mg/m²
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) 1.6 mg/m²
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) 1.8 mg/m²
Number of subjects: 24
Study: 29296761

Group type: EXPERIMENTAL
Intervention: CD34+ hematopoietic stem cell transplantation from alternative donors
Number of subjects: 10